GLPwatch
Papers (12034)
Page 132 of 201, ranked by citation count.
- Glucagon-Like Peptide 1 Receptor Agonist Use and Vertebral Fracture Risk in Type 2 Diabetes.
- Breaking the weight loss paradox: from weight reduction to cardiovascular benefit in obesity treatment.
- Efficacy of antiobesity medications for weight reduction in older adults: a systematic review.
- Pharmacology of GLP-1 agonists: describing the therapeutic potential to patients.
- Improving management of diabetic kidney disease: will GLP-1 receptor agonists have a role?
- Early-Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials.
- Defining the Intravital Renal Disposition of Fluorescence-Quenched Exenatide.
- [The new antidiabetic agents in the firing line.... safety reasons or witch hunt?].
- Efficacy and tolerability of oral semaglutide in Japanese patients with type 2 diabetes mellitus: Analysis report from diabetes specialist clinics.
- Preoperative weight loss by noninvasive approach in patients with obesity scheduled for bariatric and metabolic surgery: an update narrative review of indications and results available until 2024.
- Liraglutide shows superior cardiometabolic benefits than lorcaserin in a novel free choice diet-induced obese rat model.
- Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: A network meta-analysis.
- A single-center study on the biochemical effect and clinical effectiveness of liraglutide in Turkish patients.
- Use of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension : a systematic review.
- Obesity as a Chronic Disease: A Narrative Review of Evolving Definitions, Management Strategies, and Cardiometabolic Prioritization.
- Delayed Type Hypersensitivity Reaction Induced By Liraglutide With Tolerance to Semaglutide.
- A Study on Weight Loss Cause as per the Side Effect of Liraglutide.
- Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review.
- Single and Combined Impact of Semaglutide, Tirzepatide, and Metformin on β-Cell Maintenance and Function Under High-Glucose-High-Lipid Conditions: A Comparative Study.
- Metabolic Abnormalities Following Tirzepatide Monotherapy in Japanese Patients with Type 2 Diabetes: A Phase 3 SURPASS J-mono Post Hoc Analysis.
- Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
- Prevalence of Antiobesity Treatment and Weight-Inducing Antihyperglycemic Agents Among Patients With Type 2 Diabetes in the United States.
- In patients with HFpEF and obesity, semaglutide increased weight loss and reduced symptoms and physical limitations at 52 wk.
- The impact of preadmission/prediagnosis use of GLP-1 receptor agonists on COVID-19 mortality in patients with diabetes: A systematic review and meta-analysis.
- Persistence of Weekly Injectable Semaglutide Use in Patients with Diabetes Mellitus and Obesity: A Retrospective Follow-Up in Colombia.
- Clinical Efficacy of Once-weekly Glucagonlike Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes.
- Patient-reported outcomes of glucagon-like peptide-1 agonists on hidradenitis suppurativa severity.
- Off-label use of liraglutide in the management of a pediatric patient with type 2 diabetes mellitus.
- Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy.
- Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare.
- [Study of the effect of liraglutide on the correlation between NLRP3 inflammasome and non-alcoholic fatty liver disease].
- Should family physicians prescribe medication for obesity? YES.
- Treatment of obesity with GLP-1 receptor agonist after bariatric surgery: Real-world evidence.
- Efficacy and safety of combination of semaglutide and basal insulin in patients with of type 2 diabetes mellitus: A systematic review and meta-analysis.
- Exenatide ER-induced eosinophilia.
- Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis.
- Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Among Type 2 Diabetes Patients: Replication and Reliability Assessment Across a Research Network.
- Liraglutide improves antioxidant defense in hearts of spontaneously hypertensive female rats independently of changes in blood pressure in a pre-clinical model of menopause.
- The effects of glucagon-like peptide-1 receptor agonists on sympathetic neuron activity.
- Effect of Oral Semaglutide on Volumetric BMD and Bone Microarchitecture in Overweight/Obese Individuals with Type 2 Diabetes.
- Efficacy of liraglutide in a patient with type 2 diabetes and cryptogenic cirrhosis.
- Liraglutide effect and action in diabetes-In (LEAD-In): A prospective observational study assessing safety and effectiveness of liraglutide in patients with type 2 diabetes mellitus treated under routine clinical practice conditions in India.
- Semaglutide (Ozempic) for Type 2 Diabetes Mellitus.
- GLP-1 receptor agonists in obesity treatment: Effects on cardiometabolic variables and cardiovascular disease.
- Glycaemic control and weight loss with semaglutide in type 2 diabetes.
- Semaglutide is safe and efficacious for NASH resolution.
- Liraglutide in a real-world setting: Joint modeling of metabolic response, prediction of efficacy, and cardiovascular risk.
- Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes.
- Glucagon-like peptide-1 stimulates type 3 iodothyronine deiodinase expression in a mouse insulinoma cell line.
- Efficacy and tolerability of GLP-1 agonists in patients with type 2 diabetes mellitus: an Indian perspective.
- Rhabdomyolysis Associated With Semaglutide Therapy: A Case Report.
- The preclinical discovery and clinical evaluation of tirzepatide for the treatment of type 2 diabetes.
- Efficacy of liraglutide added to sodium-glucose cotransporter-2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post-hoc analysis of LIRA-ADD2SGLT2i.
- The promising significance of liraglutide combined with dapagliflozin or empagliflozin in the prevention of early diabetic nephropathy.
- [Exendin-4 ameliorates high glucose- and TNF-α-induced vascular endothelial cell damage by inhibiting p38 MAPK and NF-κB p65 translocation].
- Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide.
- Study Design and Baseline Characteristics of Patients with T2DM in the Post-marketing Safety Study of Dulaglutide in China (TRUST-CHN).
- Liraglutide in Combination with Insulin Has a Superior Therapeutic Effect to Either Alone on Fracture Healing in Diabetic Rats.
- Comparative Efficacy and Safety of Weekly GLP-1/GIP Agonists vs. Weekly Insulin in Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.
- Liraglutide and learning.